Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
Frontiers in Immunology|November 9, 2018
Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood TransplantationKai Cao, David Marin, Takuye Sekine, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 19, 2007
Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplantMuzaffar H Qazilbash, Rima M Saliba, Bilal Ahmed, et al.
Cancer|January 20, 2021
Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndromeBetül Oran, Rima M Saliba, Rohtesh S Mehta, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2011
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of lifeGheath Alatrash, Marcos de Lima, Nelson Hamerschlak, et al.
Bone Marrow Transplantation|December 23, 2017
Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefitBrittany Knick Ragon, Rohtesh S Mehta, Alison M Gulbis, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 11, 2015
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological MalignanciesAmin M Alousi, Jonathan E Brammer, Rima M Saliba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomasIssa F Khouri, Rima M Saliba, Chitra Hosing, et al.
Blood Advances|January 24, 2024
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantationCurtis Marcoux, Rima M Saliba, Whitney Wallis, et al.
Transplantation and Cellular Therapy|July 28, 2022
Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor TransplantationRohtesh S Mehta, Rima M Saliba, Gabriela Rondon, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2015
Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell TransplantationRyan W Jacobs, Rima M Saliba, Koji Sasaki, et al.
Pageof 10